Abstract
To screen the key immune genes in the development of cervical cancer, construct immune related gene pairs (IRGPs), and evaluate their influence on the prognosis of cervical cancer. Tumor Genome Atlas (TCGA) database and geo database were downloaded as training set and validation set respectively, and immune related gene data were downloaded from immport. IRGPs model is established by machine learning, and the model is analyzed and evaluated. Using the Uclcan to analyze the immune genes expression in cervical cancer, and to further explore the association with the expression level and the clinical stage and prognosis of cervical cancer. According to the analysis of training set, we identified 29 IRGPs as key gene pairs and constructed the model. The AUC value of the model was greater than 0.9, and the model group survival rate was conspicuous different (P < 0.001). The reliability of the model was confirmed in the validation group. Our IRGPs play an important role in the occurrence and development of cervical cancer, and can be used as a prognostic marker and potential new target of cervical cancer.
Highlights
To screen the key immune genes in the development of cervical cancer, construct immune related gene pairs (IRGPs), and evaluate their influence on the prognosis of cervical cancer
The median survival time of patients with metastatic or recurrent cervical cancer treated with platinum/taxane chemotherapy and bevacizumab can be extended to 17 months[11]
We screened immune genes that are significantly related to the prognosis of cervical cancer, constructed an immune gene pair (IRGP) model based on these genes, and used it to verify the unique prognostic markers of cervical cancer
Summary
To screen the key immune genes in the development of cervical cancer, construct immune related gene pairs (IRGPs), and evaluate their influence on the prognosis of cervical cancer. The five-year survival rate of patients with locally advanced cervical cancer can be as high as 75–85% after surgical resection, radiotherapy, chemotherapy, CRT, and so o n7. The median survival time of patients with metastatic or recurrent cervical cancer treated with platinum/taxane chemotherapy and bevacizumab can be extended to 17 months[11]. These treatments are far from enough for most locally advanced and metastatic cervical cancer patients with positive lymph node metastasis. We screened immune genes that are significantly related to the prognosis of cervical cancer, constructed an immune gene pair (IRGP) model based on these genes, and used it to verify the unique prognostic markers of cervical cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
